Source comparison
BPC-157 for SIBO Research: Full Comparison
Primary Action Mucosal repair, tight junction restoration, angiogenesis promotion Bacterial load reduction via selective gut antimicrobial activity Improved migrating motor complex (MMC) function to prevent stasis BPC-157 targets tissue repair; antimicrobials
This comparison does not assign a generated winner or score.
- Primary Action
- Mucosal repair, tight junction restoration, angiogenesis promotion
- Bacterial load reduction via selective gut antimicrobial activity
- Improved migrating motor complex (MMC) function to prevent stasis
- BPC-157 targets tissue repair; antimicrobials target overgrowth; prokinetics target motility. All three address different SIBO failure points
- Evidence Level
- Preclinical rodent models, no human SIBO trials
- Multiple RCTs in SIBO populations, FDA-approved for IBS-D (rifaximin)
- Mixed evidence; LDN has mechanistic support but limited SIBO-specific trials
- Antimicrobials have the strongest clinical evidence; BPC-157 has mechanistic plausibility but no human validation
- Symptom Recurrence Impact
- Hypothesized to reduce recurrence by restoring barrier integrity (untested in humans)
- 40–60% recurrence within 9–12 months post-treatment
- May reduce recurrence if motility dysfunction is the root cause
- Recurrence remains high across all single-modality treatments. Combination approaches likely required
- Administration Route
- Subcutaneous injection, 200–500 mcg daily (extrapolated from animal data)
- Oral tablet or capsule, 550mg TID rifaximin × 14 days
- Oral, dose-dependent on agent (e.g., 1.5–4.5mg LDN nightly)
- BPC-157 requires injection, which limits patient compliance compared to oral therapies
- Inflammatory Marker Reduction
- Demonstrated TNF-α and IL-6 reduction in preclinical models
- Indirect reduction via bacterial endotoxin load decrease
- Minimal direct anti-inflammatory effect
- BPC-157 shows the most direct anti-inflammatory action at the tissue level
- Cost & Accessibility
- Research-grade peptide, $80–150/month estimated, not FDA-approved for clinical use
- Rifaximin $1,200–1,800 per course uninsured; herbals $50–100/month
- LDN $30–60/month compounded; ginger extract $15–30/month
- BPC-157 remains in research phase; antimicrobials are expensive but covered by some insurance; prokinetics are the most affordable